Monthly Archives: May 2017

sphingotec and bestbion dx partner to market predictive biomarkers for guidance of therapy in acute heart failure and septic shock

Hennigsdorf-Berlin/Cologne  – German diagnostics company SphingoTec GmbH (Hennigsdorf) and bestbion dx GmbH (Cologne) have signed an agreement to market sphingotec’s innovative sepsis and congestive heart failure test (sphingotest® bio-ADM) and acute kidney function monitoring assay (sphingotest® penKid). Under the agreement, bestbion dx will market both biomarker assays, set to improve therapy monitoring and outcomes in…
Read more